Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been ...

AX-158 has achieved clinical validation through its phase 2a trial for the treatment of patients with mild to moderate plaque ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

"The approval of Sotyktu represents an exciting day for patients suffering from moderate-to-severe plaque psoriasis who are not satisfied with topical and conventional treatments," said Samit ...

We’ll discuss the distinct traits of psoriatic arthritis in Black patients, and the various environmental and genetic factors ...

BioArctic AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once ...

Equities research analysts at William Blair reduced their FY2024 earnings per share estimates for shares of Amgen in a ...

Crossmark Global Holdings Inc. decreased its position in Option Care Health, Inc. (NASDAQ:OPCH – Free Report) by 5.5% during ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment   TOKYO and CAMBRIDGE, Mass., Jan. 26, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: ...